BLRX BioLineRx Ltd: ערך חשבונאי למניה

BioLineRx Ltd. (BLRX) focuses on leadership in the stem cell mobilization segment and expansion into pancreatic treatment. The book value per common share illustrates the market response to this strategy, with the current level standing at 3.18. Growth is driven by Aphexda sales and royalties, while premium pricing in the US is limited only by insurance caps.

The metric is calculated as the difference between total assets and liabilities divided by the number of shares, determining the actual amount of capital attributable to a single security. An analysis of the net book value per share allows for an assessment of the intrinsic value of BioLineRx Ltd. (BLRX) amid the commercial rollout of Aphexda and the development of its oncology portfolio, revealing the gap between the market price and the business's tangible asset backing.